Y. M. Rustum, “MechanismBased Improvement in the Therapeutic Selectivity of 5FU Prodrug Alone and under Conditions of Metabolic Modulation,” Oncology, Vol. 54, No. (Suppl. 1), 1997, pp. 711. A. Lee, H. Ezzeldin, J. Fourie and R. Diasio, “Dihydro pyrimidine Dehydrgenase Deficiency: Impact of Phar macogenetics on 5Fluorouracil Therapy,” Clinical Advances in Hematology and Oncology, Vol. 2, No. 8, 2004, pp. 527532.

has been cited by the following article:

• TITLE: A Case of Advanced Multiple Hepatocellular Carcinomas with Portal Vein Tumor Thrombosis Successfully Treated by Oral Tegafur/Uracil

  AUTHORS: Hiroto Tanaka, Huuta Koga, Masako Hasegawa, Hiroshi Takihara, Eri Kimura, Tarou Inoue, Chie Ueda, Wataru Ono, Seigou Takamatsu, Yasushi Nakamura, Hiroki Ueda

  KEYWORDS: Advanced Hepatocellular Carcinoma, Portal Vein Thrombosis, Oral Tegafur/Uracil, Chemotherapy

  JOURNAL NAME: Journal of Cancer Therapy, Vol.1 No.3, September 26, 2010

  ABSTRACT: A case of advanced multiple hepatocellular carcinomas (HCC) with portal vein tumor thrombosis successfully treated by oral tegafur/uracil is reported. A 69-year-old Japanese woman with advanced HCC with tumor thrombosis underwent transcatheter arterial infusion chemotherapy in April 2001. However, 1 year later, the patient experieced a recurrence with advanced multiple HCC with portal vein tumor thrombosis and ascites. Treatment with oral tegafur/uracil was started in May 2002 and resulted in the partial response of liver tumors and the complete improvement of ascites. She remained in good health for about 6 years. This case strongly suggests that oral tegafur/uracil is an effective treatment for some cases of advanced HCC with portal vein tumor thrombosis.